Skip to content

Dr. Reddy’s launches lenalidomide capsules

Dr. Reddy’s Laboratories announced the launch, in the U.S. market, of lenalidomide capsules, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules approved by U. S. Food and Drug Administration. With this volume-limited launch, Dr.

Table of Contents

PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch, in the U.S. market, of lenalidomide capsules, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules approved by U. S. Food and Drug Administration.

With this volume-limited launch, Dr. Reddy’s is eligible for first-to-market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5 mg and 20 mg strengths.

Comments

Latest